Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PLAGL2
REST API REST API
Homo sapiens
PLAGL2 is differentially expressed in 277 experiments: 119 organism parts: testis, liver, ... (117 more);, 210 disease states: normal, colon carcinoma, ... (208 more);, 85 cell types 436 cell lines 49 compound treatments and 75 other conditions.
Synonyms ZNF900
Orthologs PLAGL2 (Gallus gallus)   plagl2 (Danio rerio)   Plagl2 (Mus musculus)   plagx (Danio rerio)   PLAGL2 (Bos taurus)   Plagl2 (Rattus norvegicus)   PLAGL2 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, metal ion binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, nucleus, zinc ion binding, sequence-specific DNA binding transcription factor activity
UniProt Accession Q9UPG8
Search EB-eye ENSG00000126003
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
U87
2
E-GEOD-20089, E-MEXP-903
HepG2
2
E-GEOD-21154, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
T84
2
E-GEOD-1474, E-MTAB-37
430 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-145, E-TABM-130
not specified
2
E-GEOD-11755, E-GEOD-18811
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-MEXP-1327
fibroblast
1
2
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
germ cell
1
E-MTAB-25
79 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, ... (58 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-GEOD-3726, E-MTAB-62, E-MTAB-57
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic lymphocytic leukemia
1
2
E-GEOD-6691, E-MTAB-37, E-GEOD-2466
204 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
none
3
4
E-GEOD-5824, E-MEXP-1958, E-MEXP-1601, E-TABM-868, E-MEXP-1230, ... (7 experiments)
BCR/ABL1
1
1
E-GEOD-15811
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
potassium dichromate
1
E-GEOD-6907
no estradiol
1
E-GEOD-20081
43 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
50
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-TABM-321, E-TABM-868, E-TABM-601, E-GEOD-1153, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-6432, E-MEXP-2657, E-TABM-127, E-GEOD-20540, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.546 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM